Publication

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort

Journal Paper/Review - Mar 5, 2019

Units
Keywords
lung cancer
Contact

Citation
Schmid S, Aeppli S, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort. Lung Cancer 2019
Type
Journal Paper/Review (English)
Journal
Lung Cancer 2019
Publication Date
Mar 5, 2019
Brief description/objective

Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) with antitumor activity in non-small cell lung cancer (NSCLC) with EGFR T790M mutations. The incidence of oligo-progression (PD) on osimertinib is
unknown.